Brief: Neurovive Proposes A Rights Issue Of SEK 74 Mln

Abliva AB

19/02/2020 07:33

Feb 19 (Reuters) - NeuroVive Pharmaceutical AB  NVP.ST :
    * NEUROVIVE PROPOSES A RIGHTS ISSUE OF MSEK 74 AND
ACCELERATES THE
CLINICAL DEVELOPMENT OF KL1333
    * RESOLVED ON RIGHTS ISSUE IN ORDER TO ENSURE THAT CO HAS
FINANCIAL RESOURCES FOR ITS PRIORITIZED PRIMARY MITOCHONDRIAL
DISEASE (PMD) PROGRAMS, PRIMARILY CONTINUED CLINICAL DEVELOPMENT
OF KL1333
    * UPON FULL SUBSCRIPTION IN RIGHTS ISSUE SHARE CAPITAL WILL
INCREASE FROM SEK 9,297,629.55 TO SEK 13,946,444.30 AND NUMBER
OF SHARES WILL INCREASE FROM 185,952,591 SHARES TO 278,928,886
SHARES
    * APRIL 6 - 24, 2020 SUBSCRIPTION PERIOD
    * SUBSCRIPTION PRICE AMOUNTS TO SEK 0.80 PER SHARE, WHICH
IMPLIES
THAT COMPANY WILL RAISE APPROXIMATELY MSEK 74 BEFORE ISSUE COSTS
FROM RIGHTS ISSUE
    * TWO (2) SUBSCRIPTION RIGHTS ENTITLE TO SUBSCRIPTION OF ONE
(1)
NEW SHARE
    * SUBSCRIPTION PRICE AMOUNTS TO SEK 0.80 PER SHARE

Source text for Eikon:  ID:nWkr6cxspd 
Further company coverage:  NVP.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))